Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: PULSE OXIMETRY
Interventions: NO INTERVENTION; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Parkinson Disease
Interventions: Ketone Ester Beverage, Electrolyte Beverage, Cycling Intervention; Dietary Supplement · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis
Interventions: lumacaftor, ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Cancer, Chemotherapy
Interventions: Virtual reality therapy, Questionnaires, Measure heart rate, Cyber sickness measurement; Behavioral · Procedure
Lead sponsor: Cody Stansel; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: Ciprofloxacin Extended-Release Tablets 1000 mg, Cipro® XR Tablets 1000 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 95
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Stereotactic body radiotherapy, Traditional Palliation; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2); Biological · Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: End-Stage Renal Disease
Interventions: Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
Interventions: Everolimus 10 mg, Octreotide Depot; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: ARDS, Sepsis, Pneumonia
Interventions: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan; Other · Procedure · Radiation
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers, Sjögren's Syndrome
Interventions: ASP5502, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Participants
Interventions: Mavorixafor, Carbamazepine, Efavirenz; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Resistant or Refractory Solid Tumors
Interventions: CAL056 mesylate; Drug
Lead sponsor: Calgent Biotechnology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • San Antonio, Texas

Conditions: Healthy
Interventions: Divalproex Sodium, Depakote®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Belzutifan; Drug
Lead sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Renal Impairment
Interventions: Fruquintinib; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy Volunteers
Interventions: Insulin, Taste Task, Magnetic Resonance Imaging, Dextrose; Drug · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 30 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: ALXN1840, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: PreDiabetes
Interventions: Transform10 Diabetes Prevention Program; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Migraine, Trigger Induced Migraine
Interventions: Rimegepant 75 MG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: McLean, Virginia

Search by objective public record fields.

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

SPO2 VALIDATION STUDY - PHILIPS FAST 2025

Effects of Exercise Training and Ketone Ester on Muscle Strength and Cardiovascular Response in Parkinson's Disease

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic

Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

The APS Phenotyping Study

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Drug-Drug Interaction Potential of Mavorixafor

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions

A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets

Fruquintinib Renal Impairment Study

Insulin Modulation of fMRI Connectivity in Healthy Adults

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

Digital Diabetes Prevention Program Study

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US